Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q35208654)
Watch
English
Targeting the HER/EGFR/ErbB family to prevent breast cancer.
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
3171200
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21816844%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
review article
1 reference
stated in
Europe PubMed Central
title
Targeting the HER/EGFR/ErbB family to prevent breast cancer
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
3171200
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21816844%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
author
Louise R Howe
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
3171200
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21816844%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
author name string
Powel H Brown
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
3171200
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21816844%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
publication date
1 August 2011
1 reference
stated in
Europe PubMed Central
PMC publication ID
3171200
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21816844%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
published in
Cancer Prevention Research
1 reference
stated in
Europe PubMed Central
PMC publication ID
3171200
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21816844%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
volume
4
1 reference
stated in
Europe PubMed Central
PMC publication ID
3171200
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21816844%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
issue
8
1 reference
stated in
Europe PubMed Central
PMC publication ID
3171200
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21816844%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
page(s)
1149-1157
1 reference
stated in
Europe PubMed Central
PMC publication ID
3171200
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21816844%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
cites work
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Preventive therapy for breast cancer: a consensus statement
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
13 July 2018
Lapatinib, a preventive/therapeutic agent against mammary cancer, suppresses RTK-mediated signaling through multiple signaling pathways
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
26 September 2018
Exemestane for breast-cancer prevention in postmenopausal women.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
26 September 2018
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
26 September 2018
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
26 September 2018
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
26 September 2018
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
26 September 2018
Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
26 September 2018
Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
26 September 2018
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
26 September 2018
HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
26 September 2018
Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
26 September 2018
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
26 September 2018
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171200
retrieved
26 September 2018
Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma--a detailed morphological analysis
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/21816844
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/21816844
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/21816844
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/21816844
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1158/1940-6207.CAPR-11-0334
1 reference
stated in
Europe PubMed Central
PMC publication ID
3171200
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21816844%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
PMC publication ID
3171200
1 reference
stated in
Europe PubMed Central
PMC publication ID
3171200
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21816844%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
PubMed publication ID
21816844
1 reference
stated in
Europe PubMed Central
PMC publication ID
3171200
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21816844%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 February 2020
ResearchGate publication ID
51547434
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit